Toute l’ingéniosité et la vitalité d’Oncodesign via notre espace ressources

Service

Meet Oncodesign in person this spring
Corporate
Service
27/04/2022

[Congress] Meet Oncodesign in person this spring

Check out where to meet Oncodesign this spring... surely we can arrange a meeting somewhere.

Oncology Webinar
Service
05/04/2022

[EN] How to Better Optimize an Oncology Drug Discovery Program

Watch this oncology webinar on preclinical pharmacology, covering all step of the drug discovery journey from target validation to clinical studies...

Scientific Resources | Oncodesign
Service
28/03/2022

Scientific Posters | AACR 2022

Find all 4 posters that are presented during AACR 2022. They unveil our expertise in oncology using our scientific know-how (medicinal chemistry, radio-imaging, in vivo model and microbiome)

[CONGRESS] Microbiome & Probiotics
Service
18/03/2022

[Congress] AACR Annual Meeting | 8-13 April 2022

Meet us in person at the Annual Meeting of the AACR in New Orleans!

Oncology Webinar
Service
16/03/2022

[Webinar] How to better optimize an oncology drug discovery program

Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.

[CONGRESS] Microbiome & Probiotics
Service
14/03/2022

[CONGRESS] Microbiome & Probiotics, 29-30 March 2022

Meet us at the Microbiome & Probiotics congress in San Diego | March 2022. Explore our expertise in assessing the role of microbiome in drug discovery

Drive-Biologics - Discovery & Developement | Oncodesign
Service
24/02/2022

Abzena, Alira Health et Oncodesign lancent DRIVE-Biologics, une nouvelle offre de services premium

A lire le CP sur l'offre conjointe Abzena x Alira Heath x Oncodesign : une nouvelle solution intégrée unique depuis la découverte de biologiques jusqu'à leur fabrication clinique et leur commercialisation.

Service
22/02/2022

ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance [EN]

A lire dans Communication Biologics (Nature), les données du programme préclinique exoSTING, auquel Oncodesign a participé (Hepa1-6).

Service
18/02/2022

Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity [EN)

A lire dans Science Advances : le programme de développement préclinique d'exoASO-STAT6, un nouveau candidat de médecine de précision à base d'exosomes pour le traitement des tumeurs riches en macrophages.

Service
14/01/2022

[Congress] Microbiome Movement Drug Development

Oncodesign will be at the digital event Microbiome Movement Drug Development. Take the opportunity to learn more about SOLO Microbiome.

Service
11/12/2021

Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections

SARS-CoV-2; antiviral drug combination; hepatitis C virus; hepatitis E virus; human immunodeficiency virus; influenza A virus; interferon-alpha.

Service
07/12/2021

[EN] Preclinical Models for Microbiome Research in Oncology and Inflammatory Diseases

Learn how current in vivo preclinical models meet the needs of microbiome research and innovation while outlining their limitations and the challenges still to be overcome in this growing field.